Improving Clinical Decision Making with Engaging CME, Tools, & Resources
MH Risk Factors After RRD Repair
Maria H. Berrocal, MD
Avni P. Finn, MD, MBA
Signaling for Sustained Change: Spotlight on the Potential of TKIs to Deliver Durable Control of Exudative Retinal Disease
Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion
Ashkan Abbey, MD
Retinal Vein Occlusion: The Case for Prompt Treatment
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Outcomes for PDR Patients LTFU for at Least 1 Year
Kyle Davis Kovacs, MD
Matt Starr, MD
Nita Valikodath, MD, MS
Examining Therapeutic Timing in RVO-Related Macular Edema
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Lejla Vajzovic, MD, FASRS
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
GLP-1 Use and AMD Risk
Barton Lynn Blackorby, MD
Katharine Talcott, MD
Hong-Uyen Hua, MD
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Ryan Quigley
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Esther Lee Kim, MD
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Danny Mammo, MD
Practice Efficiency and Innovation
Jacob Lang
Elevating Clinical Efficiency
Diana Chu
Tailored Treatment in Retinal Disease: Using Biomarkers to Guide Anti-VEGF Therapy
Jennifer Caudle, DO, FACOFP
Michael Javaheri, MD, MSc, FASRS
Loading...
We're glad to see you're enjoying Eye Health Academy… but how about a more personalized experience?
Press cancel to remain on Eye Health Academy. Press the link below or the continue button to keep going.